These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 34132615)

  • 1. Spike Protein Antibodies Mediate the Apparent Correlation between SARS-CoV-2 Nucleocapsid Antibodies and Neutralization Test Results.
    Perkmann T; Koller T; Perkmann-Nagele N; Klausberger M; Duerkop M; Holzer B; Hartmann B; Mucher P; Radakovics A; Ozsvar-Kozma M; Wagner OF; Binder CJ; Haslacher H
    Microbiol Spectr; 2021 Sep; 9(1):e0021821. PubMed ID: 34132615
    [No Abstract]   [Full Text] [Related]  

  • 2. SARS-CoV-2 antibodies: Comparison of three high-throughput immunoassays versus the neutralization test.
    Laterza R; Schirinzi A; Bruno R; Genco R; Contino R; Ostuni A; Di Serio F
    Eur J Clin Invest; 2021 Jul; 51(7):e13573. PubMed ID: 33870493
    [No Abstract]   [Full Text] [Related]  

  • 3. Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection.
    Rosati M; Terpos E; Ntanasis-Stathopoulos I; Agarwal M; Bear J; Burns R; Hu X; Korompoki E; Donohue D; Venzon DJ; Dimopoulos MA; Pavlakis GN; Felber BK
    Front Immunol; 2021; 12():793953. PubMed ID: 34899762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody Response against SARS-CoV-2 and Seasonal Coronaviruses in Nonhospitalized COVID-19 Patients.
    Ruetalo N; Businger R; Althaus K; Fink S; Ruoff F; Pogoda M; Iftner A; Ganzenmüller T; Hamprecht K; Flehmig B; Bakchoul T; Templin MF; Schindler M
    mSphere; 2021 Feb; 6(1):. PubMed ID: 33627511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2 Serologic Assays in Control and Unknown Populations Demonstrate the Necessity of Virus Neutralization Testing.
    Rathe JA; Hemann EA; Eggenberger J; Li Z; Knoll ML; Stokes C; Hsiang TY; Netland J; Takehara KK; Pepper M; Gale M
    J Infect Dis; 2021 Apr; 223(7):1120-1131. PubMed ID: 33367830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of serological anti-SARS-CoV-2 chemiluminescent immunoassays correlated to live virus neutralization test, for the detection of anti-RBD antibodies as a relevant alternative in COVID-19 large-scale neutralizing activity monitoring.
    Cristiano A; Pieri M; Sarubbi S; Pelagalli M; Calugi G; Tomassetti F; Bernardini S; Nuccetelli M
    Clin Immunol; 2022 Jan; 234():108918. PubMed ID: 34971839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of SARS-CoV-2 neutralizing antibodies using a vesicular stomatitis virus possessing SARS-CoV-2 spike protein.
    Tani H; Kimura M; Tan L; Yoshida Y; Ozawa T; Kishi H; Fukushi S; Saijo M; Sano K; Suzuki T; Kawasuji H; Ueno A; Miyajima Y; Fukui Y; Sakamaki I; Yamamoto Y; Morinaga Y
    Virol J; 2021 Jan; 18(1):16. PubMed ID: 33435994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal Serological Analysis and Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent Patients.
    Muecksch F; Wise H; Batchelor B; Squires M; Semple E; Richardson C; McGuire J; Clearly S; Furrie E; Greig N; Hay G; Templeton K; Lorenzi JCC; Hatziioannou T; Jenks S; Bieniasz PD
    J Infect Dis; 2021 Feb; 223(3):389-398. PubMed ID: 33140086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The complexities of SARS-CoV-2 serology.
    Houlihan CF; Beale R
    Lancet Infect Dis; 2020 Dec; 20(12):1350-1351. PubMed ID: 32979317
    [No Abstract]   [Full Text] [Related]  

  • 10. Association between SARS-CoV-2 Neutralizing Antibodies and Commercial Serological Assays.
    Tang MS; Case JB; Franks CE; Chen RE; Anderson NW; Henderson JP; Diamond MS; Gronowski AM; Farnsworth CW
    Clin Chem; 2020 Dec; 66(12):1538-1547. PubMed ID: 32894750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetics of Nucleocapsid, Spike and Neutralizing Antibodies, and Viral Load in Patients with Severe COVID-19 Treated with Convalescent Plasma.
    Thomopoulos TP; Rosati M; Terpos E; Stellas D; Hu X; Karaliota S; Bouchla A; Katagas I; Antoniadou A; Mentis A; Papageorgiou SG; Politou M; Bear J; Donohue D; Kotanidou A; Kalomenidis I; Korompoki E; Burns R; Pagoni M; Grouzi E; Labropoulou S; Stamoulis K; Bamias A; Tsiodras S; Dimopoulos MA; Pavlakis GN; Pappa V; Felber BK
    Viruses; 2021 Sep; 13(9):. PubMed ID: 34578426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative SARS-CoV-2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C).
    Rostad CA; Chahroudi A; Mantus G; Lapp SA; Teherani M; Macoy L; Tarquinio KM; Basu RK; Kao C; Linam WM; Zimmerman MG; Shi PY; Menachery VD; Oster ME; Edupuganti S; Anderson EJ; Suthar MS; Wrammert J; Jaggi P
    Pediatrics; 2020 Dec; 146(6):. PubMed ID: 32879033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Assessment of Serological Assays for SARS-CoV-2 as Surrogates for Authentic Virus Neutralization.
    Wohlgemuth N; Whitt K; Cherry S; Kirkpatrick Roubidoux E; Lin CY; Allison KJ; Gowen A; Freiden P; Allen EK; ; Gaur AH; Estepp JH; Tang L; Mori T; Hijano DR; Hakim H; McGargill MA; Krammer F; Whitt MA; Wolf J; Thomas PG; Schultz-Cherry S
    Microbiol Spectr; 2021 Oct; 9(2):e0105921. PubMed ID: 34704832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Towards Quantitative and Standardized Serological and Neutralization Assays for COVID-19.
    Tian L; Elsheikh EB; Patrone PN; Kearsley AJ; Gaigalas AK; Inwood S; Lin-Gibson S; Esposito D; Wang L
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33800363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamic Assay for Profiling Anti-SARS-CoV-2 Antibodies and Their ACE2/Spike RBD Neutralization Capacity.
    Phelan T; Dunne J; Conlon N; Cheallaigh CN; Abbott WM; Faba-Rodriguez R; Amanat F; Krammer F; Little MA; Hughes G; Bergin C; Kerr C; Sundaresan S; Long A; McCormack W; Brady G
    Viruses; 2021 Jul; 13(7):. PubMed ID: 34372581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Standardised neutralising antibody assays are needed for evaluating COVID-19 vaccines.
    Wang Y
    EBioMedicine; 2021 Nov; 73():103677. PubMed ID: 34742128
    [No Abstract]   [Full Text] [Related]  

  • 17. A Highly Sensitive and Specific SARS-CoV-2 Spike- and Nucleoprotein-Based Fluorescent Multiplex Immunoassay (FMIA) to Measure IgG, IgA, and IgM Class Antibodies.
    Solastie A; Virta C; Haveri A; Ekström N; Kantele A; Miettinen S; Lempainen J; Jalkanen P; Kakkola L; Dub T; Julkunen I; Melin M
    Microbiol Spectr; 2021 Dec; 9(3):e0113121. PubMed ID: 34787485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of spike mutations on SARS-CoV-2 neutralization.
    Rees-Spear C; Muir L; Griffith SA; Heaney J; Aldon Y; Snitselaar JL; Thomas P; Graham C; Seow J; Lee N; Rosa A; Roustan C; Houlihan CF; Sanders RW; Gupta RK; Cherepanov P; Stauss HJ; Nastouli E; ; Doores KJ; van Gils MJ; McCoy LE
    Cell Rep; 2021 Mar; 34(12):108890. PubMed ID: 33713594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SARS-CoV-2 Neutralizing Antibody Responses towards Full-Length Spike Protein and the Receptor-Binding Domain.
    Bayarri-Olmos R; Idorn M; Rosbjerg A; Pérez-Alós L; Hansen CB; Johnsen LB; Helgstrand C; Zosel F; Bjelke JR; Öberg FK; Søgaard M; Paludan SR; Bak-Thomsen T; Jardine JG; Skjoedt MO; Garred P
    J Immunol; 2021 Aug; 207(3):878-887. PubMed ID: 34301847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mild SARS-CoV-2 Illness Is Not Associated with Reinfections and Provides Persistent Spike, Nucleocapsid, and Virus-Neutralizing Antibodies.
    Schuler CF; Gherasim C; O'Shea K; Manthei DM; Chen J; Zettel C; Troost JP; Kennedy AA; Tai AW; Giacherio DA; Valdez R; Baldwin JL; Baker JR
    Microbiol Spectr; 2021 Oct; 9(2):e0008721. PubMed ID: 34468184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.